Juan Manuel Ramirez-Anguita
Overview
Explore the profile of Juan Manuel Ramirez-Anguita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie J, Lopez-Guell K, Dedman D, Duarte-Salles T, Kolde R, Lopez-Blasco R, et al.
EClinicalMedicine
. 2024 Nov;
77:102903.
PMID: 39552716
Background: The World Health Organisation (WHO) has identified a range of symptomatic manifestations to aid in the clinical diagnosis of post-COVID conditions, herein referred to as post-acute COVID-19 symptoms. We...
2.
Dernie F, Corby G, Robinson A, Bezer J, Mercade-Besora N, Griffier R, et al.
Pharmacoepidemiol Drug Saf
. 2024 Nov;
33(11):e70042.
PMID: 39532529
Purpose: The generation of representative disease phenotypes is important for ensuring the reliability of the findings of observational studies. The aim of this manuscript is to outline a reproducible framework...
3.
Du M, Dernie F, Catala M, Delmestri A, Man W, Brash J, et al.
Eur J Intern Med
. 2024 Aug;
130:106-117.
PMID: 39134452
Objective: Multiple treatment options are recommended for Systemic Lupus Erythematosus (SLE) by clinical guidelines. This study aimed to explore SLE treatment patterns as there is limited real-world data of SLE...
4.
Mortier P, Conde S, Alayo I, Amigo F, Ballester L, Cirici Amell R, et al.
JAMA Netw Open
. 2024 Jun;
7(6):e2417131.
PMID: 38922620
Importance: There is a need for representative research on serious adverse outcomes following discharge from psychiatric hospitalization. Objective: To compare rates of premature death, suicide, and nonlethal intentional self-harm after...
5.
Burkard T, Lopez-Guell K, Gorbachev A, Bellas L, Jodicke A, Burn E, et al.
Pharmacoepidemiol Drug Saf
. 2024 May;
33(6):e5809.
PMID: 38773798
Purpose: We aimed to develop a standardized method to calculate daily dose (i.e., the amount of drug a patient was exposed to per day) of any drug on a global...
6.
Mercade-Besora N, Guo Y, Du M, Li X, Ramirez-Anguita J, Moreno A, et al.
Arthritis Care Res (Hoboken)
. 2024 Mar;
76(8):1173-1178.
PMID: 38523562
Objective: We studied whether the use of hydroxychloroquine (HCQ) for COVID-19 resulted in supply shortages for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods: We used US...
7.
Mortier P, Amigo F, Bhargav M, Conde S, Ferrer M, Flygare O, et al.
BMC Psychiatry
. 2024 Mar;
24(1):220.
PMID: 38509500
Background: Self-harm presents a significant public health challenge. Emergency departments (EDs) are crucial healthcare settings in managing self-harm, but clinician uncertainty in risk assessment may contribute to ineffective care. Clinical...
8.
Makadia R, Shoaibi A, Rao G, Ostropolets A, Rijnbeek P, Voss E, et al.
JAMIA Open
. 2023 Nov;
6(4):ooad096.
PMID: 38028730
Objective: Developing accurate phenotype definitions is critical in obtaining reliable and reproducible background rates in safety research. This study aims to illustrate the differences in background incidence rates by comparing...
9.
Gauffin O, Brand J, Vidlin S, Sartori D, Asikainen S, Catala M, et al.
Drug Saf
. 2023 Oct;
46(12):1335-1352.
PMID: 37804398
Introduction: Individual case reports are the main asset in pharmacovigilance signal management. Signal validation is the first stage after signal detection and aims to determine if there is sufficient evidence...
10.
Sanz F, Pognan F, Steger-Hartmann T, Diaz C, Asakura S, Amberg A, et al.
Nat Rev Drug Discov
. 2023 Jun;
22(8):605-606.
PMID: 37316648
No abstract available.